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Original ArticleGroup Changes in Cognitive Performance After Surgery Mask Changes in Individual
Patients with GlioblastomaInge S. van Loenen1, Sophie J.M. Rijnen1,2, Jimme Bruijn1,2, Geert-Jan M. Rutten2, Karin Gehring1,2,
Margriet M. Sitskoorn1-BACKGROUND: There is a growing interest to include
evaluations of cognitive performance in the clinical man-
agement of patients with glioblastoma (GBM). However, as
changes in cognitive performance of a group may mask
changes in individual patients, study results are often
difficult to transfer into clinical practice. We focused on
the comparison of group versus individual changes in
neuropsychological performance of patients with GBM
after initial surgical treatment.
-METHODS: Patients underwent neuropsychological
evaluation using CNS Vital Signs 1 day prior to and 3
months after surgery. Two-tailed paired-samples t tests
were conducted to assess changes on the group level.
Reliable change indices (RCIs) that correct for practice
effects and imperfect test-retest reliabilities were used to
examine changes in individual patients.
-RESULTS: Cognitive dysfunction was common (>80%)
both before and 3 months after surgery in this sample of 82
patients with GBM. Whereas group analyses revealed
minimal changes in performance over time, RCIs demon-
strated that most patients (89%) showed changes in per-
formance in at least 1 cognitive domain. Half of these
individual patients solely showed improvements, a quarter
solely showed declines, and another quarter showed both
improvements and declines.
-CONCLUSIONS: This study clearly demonstrates that






- Reliable change index
Abbreviations and Acronyms
CNS VS: CNS Vital Signs
ES: Effect size
GBM: Glioblastoma
RCI: Reliable change index
e172 www.SCIENCEDIRECT.com WORLD NEwhen looking only at group results. Future studies should
more often use an individual patient approach to enhance
knowledge transfer into clinical practice.INTRODUCTIONlioblastoma (GBM) is the most common and malignant
type of primary brain tumor, and current standard ofGcare is maximal safe resection followed by radio- and
chemotherapy.1-3 Candidates for resective surgery should be in a
reasonable general and neurological condition. In addition, the
estimated risks of surgery should be acceptable in terms of post-
operative neurological deficits. The decision whether to operate or
not is thus largely based on clinical grounds and predominantly
focuses on the patients’ general performance status (e.g., Kar-
nofsky Performance Status Scale)4 and their sensorimotor and
language capabilities. Although current guidelines stress the
importance of cognitive functioning, and prior studies
demonstrate cognitive deficits in patients with GBM already
prior to surgery, information on the patient’s cognitive status is
currently seldom embedded in the clinical management of GBM
patients.3,5-12
It is well known that cognitive deficits can contribute to a lower
quality of life of the patient.13,14 Also, cognitive dysfunction has
been found to be a valuable indicator of disease severity, and
potentially even for tumor progression.15,16 Therefore, there is
growing interest to include the results of neuropsychological ex-
aminations into neuro-oncological practice. Such informationFrom the 1Department of Cognitive Neuropsychology, Tilburg University, Tilburg; and the
2Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
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surgical techniques (e.g., using 5-aminolevulinic A) that push the
boundaries of resection, but at the same time potentially endanger
brain functioning.17-19
Prior studies on group-level cognitive function have found wide-
spread preoperative cognitive impairment, with modest yet signifi-
cant improvements in memory and information processing
speed,6,9,20 and declines in language and executive function post-
operatively.20-22 However, results on performance of a group of pa-
tients may mask performance in individual patients, thereby making
results difficult to transfer into clinical practice.23 Only very few
studies focused on individual cognitive performance and change
over time in patients with GBM. These studies demonstrated
improved performance in 24%e49% and declined performance in
23%e38% of the patients postoperatively, where most changes
were found in verbal memory, attention, and executive
functioning.6,20 Overall, improvements of performance were more
frequent than declines after surgery, despite a worsening of perfor-
mance immediately after surgery.6,20,24 In these studies, fairly simple
measures of change in performance (e.g., raw difference scores,
subtracting preoperative from postoperative scores) were adopted.
Previously, Wefel et al.25 adopted the widely used plain version of the
reliable change index (RCI) of Jacobson andTruax23 to assess changes
in cognitive performance of patients with recurrent GBM treated with
bevacizumab. However, to decide on reliable changes in
performance, one should account for very common methodological
phenomena related to repeated neuropsychological assessment,
such as practice effects.26 Interpreting performance without
considering, for instance, practice effects might result in
overestimations of improvement, or underestimations of decline in
performance.
In this study, cognitive impairments before and 3 months after
initial surgical treatment were evaluated using a brief, computer-
ized neuropsychological assessment (i.e., CNS Vital Signs [CNS
VS] [CNS Vital Signs, LLC, Morrisville, North Carolina, USA])27
that was implemented into clinical neuro-oncological care of pa-
tients with GBM. Furthermore, since we expect that declines and
improvements of individual patients may be masked when looking
at performance on the group level, we focused on the comparison
of group versus reliable individual changes in neuropsychological
performance of patients with GBM from pre- to postsurgery.METHODS
Patients
We included patients who underwent resective surgery between
January 2011 and March 2016. Based on tissue obtained during
surgery, all patients were diagnosed with a newly, histopatho-
logically confirmed GBM.
Exclusion criteria were 1) age below 18 years, 2) previous
intracranial neurosurgery, 3) recent (2 years) neurologic or psy-
chiatric disorders, 4) other major medical illnesses in the past year
prior to surgery (e.g., cancer, myocardial infarct), 5) lack of basic
proficiency in Dutch, 6) premorbid intelligence quotient below 85,
and 7) inability to undergo neuropsychological assessment
because of severe visual, motor, or cognitive problems.WORLD NEUROSURGERY 117: e172-e179, SEPTEMBER 2018All patients provided written informed consent. The study was
approved by the medical ethics committee (file number
NL41351.008.12).
Measures and Procedure
Patients’ Characteristics. Patients underwent neuropsychological
evaluation per protocol 1 day before (T0) and 3 months after
surgery (T3) as part of clinical care. Number of years of education
was self-reported by patients during a standardized interview.
Clinical information (i.e., data on medication use and adjuvant
radio- or chemotherapy) was retrieved from electronic medical
charts. Tumor location was identified by the neurosurgeon.
Maximum tumor diameter (in axial, sagittal, or coronal plane) was
determined by 3 trained researchers under direct supervision of
the neurosurgeon, using contrast-enhanced T1-weighted magnetic
resonance images.
CNS VS. The formal Dutch translation of the computerized neu-
ropsychological battery CNS VS was used to examine cognitive
performance.27 CNS VS is widely used to assess cognitive
functioning in patient groups (e.g., in patients with
meningioma,28 mild cognitive impairment, and early dementia29).
It consists of 7 neuropsychological tests that are based on paper-
and-pencil tests, yielding measures of performance on 11 cogni-
tive domains.25 Because some domains are largely based on the
same test scores, we only considered the following 7 domains:
verbal memory, visual memory, processing speed, psychomotor
speed, reaction time, complex attention, and cognitive flexibility.
After completing the battery raw cognitive domain scores, among
others, were provided.
It takes 30e40 minutes to complete the CNS VS. Assessments
were performed using the CNS VSX local software app, on a laptop
computer running a 64-bit operating system. Background pro-
grams were shut down, and there were no connections to Internet
resources. Well-trained test technicians remained present during
the entire assessment.
Statistical Analyses
Patients’ Characteristics. Descriptive and comparative analyses of
sociodemographic and clinical variables, and baseline cognitive
performance of the patients who completed both assessments,
versus patients who dropped out before follow-up, were
performed.
CNS VS Normed Cognitive Domain Scores. Effects of sociodemo-
graphic (i.e., age, sex, education) variables on performance, and
practice effects between the first and second assessment were
found to be present in a Dutch normative sample.30,31 Therefore,
raw cognitive domain scores of the patients were converted into
sociodemographically adjusted z scores. With respect to the
postoperative scores, practice effects were corrected for, in addi-
tion to the sociodemographic corrections.
Group-Level Performance. To explore differences in mean CNS VS
performance on the 7 cognitive domains between patients with
GBM and the normative sample before and 3 months after surgery,
one-tailed one-sample z tests were performed (test values: mean z¼
0, SD¼ 1). To examine themagnitude of differences, we considered
the mean z score for each cognitive domain (representing thewww.WORLDNEUROSURGERY.org e173
Figure 1. Flowchart of patients with glioblastoma eligible for inclusion
and follow-up. GBM, glioblastoma; T0, preoperatively; T3,
postoperatively.




Age (years), mean  SD (range) 58.6  11.9 (18e81)
Education (years), mean  SD* 13.7  3.3
Sex, female/male 41 (33)/84 (67)
Clinical characteristics













Tumor diameter (mm), mean  SD (range)y 54  15 (18e101)




AEDs and corticosteroids 18 (14)
Unknown 9 (7)
Additional treatment between T0 and T3
None 3 (4)
Radiotherapy 8 (9)
Radiotherapy and chemotherapy 71 (87)
Values are number of patients (%) or as otherwise indicated.
AED, antiepileptic drug; T0, preoperatively; T3, postoperatively.
*Number of years of completed education.
yIn the axial, sagittal, or coronal plane, as determined by using contrast-enhanced T1-
weighted magnetic resonance imaging.
ORIGINAL ARTICLE
INGE S. VAN LOENEN ET AL. CHANGES IN COGNITIVE PERFORMANCE OF GBM PATIENTSdifference between the patient sample and the normative sample in
terms of SDs) as the effect size (ES). This equals Cohen’s d ES when
calculated according to the formula Meanpatients Meancontrols/SD,
as here againMeancontrols¼ 0 and SD¼ 1. Small, medium, and large
effects are considered to be represented by d 0.50, d between 0.51
and 0.80, and d  0.80, respectively.32
Change. Two-tailed samples t tests were conducted to assess
changes over time in cognitive domain scores on the group level.
ES were calculated and expressed as Cohen’s d following the
formula: MeandifferenceT3  T0/SDdifference. Again, d  0.50 ¼ small
effect, d between 0.51 and 0.80 ¼ medium effect, and d  0.80 ¼
large effect.32
Individual Performance. To categorize cognitive performance of
individual patients, z scores of 2.00 were classified as very low,
scores between 1.99 and 1.50 as low, scores between 1.49
and 1.49 as average, and scores of  1.50 as high.33 Performance
was defined as impaired if the z score fell in the very low or low
category (1.50). The numbers and percentages of patients
scoring within each category for cognitive domains, and the
number of impaired domains, were counted for both time points.
Changes. In order to determine whether observed changes in scores
reliably reflect true changes in performance while taking into ac-
count methodological confounds (e.g., practice effects, imperfect
test-retest reliabilities), RCI values were calculated for each domain
for each patient. A standardized regression-based RCI described by
Maassen et al.26 was adopted. Rijnen et al.31 described details
regarding the RCI formulae for changes in CNS VS performance,
which are established based on results on repeated testing in a
Dutch normative sample (N ¼ 158) at baseline and 3-month
follow up. RCI formulae were established for each cognitive
domain. No effects of age, sex, and education on changes over time
in the normative sample were found; consequently, these variablese174 www.SCIENCEDIRECT.com WORLD NEwere not included in the formulae. Change was defined by RCI
values exceeding 1.645 (corresponding with a 2-tailed a of 0.10,
90% confidence interval), where positive values represented
improvement, and negative values represented declined perfor-
mance. The numbers of patients with improved, stable, or declined
cognitive performance were counted for each cognitive domain. In
addition, a Chi-square test of independence was conducted to
compare the proportion of patients with GBM in whoseUROSURGERY, https://doi.org/10.1016/j.wneu.2018.05.232
Table 2. Comparison of Mean Performance of Patients with Glioblastoma Pre- and Postoperatively
Cognitive Domain* Mean z Score  SD Number of Patientsy z Test p Value Cohen’s dz
Preoperative assessmentx
Verbal memory 0.91  1.28 117 9.82 <0.001k 0.91
Visual memory 0.96  1.28 120 10.57 <0.001k 0.96
Processing speed 1.45  1.37 122 16.09 <0.001k 1.45
Psychomotor speed 1.59  1.84 121 17.72 <0.001k 1.59
Reaction time 2.16  2.85 117 23.58 <0.001k 2.16
Complex attention 2.98  3.23 117 32.29 <0.001k 2.98
Cognitive flexibility 2.36  2.53 116 25.37 <0.001k 2.36
Postoperative assessment
Verbal memory 0.89  1.39 77 7.79 <0.001k 0.89
Visual memory 0.69  1.20 78 6.05 <0.001k 0.69
Processing speed 1.27  1.24 81 10.84 <0.001k 1.27
Psychomotor speed 1.20  1.54 81 11.42 <0.001k 1.20
Reaction time 2.22  2.60 82 20.11 <0.001k 2.22
Complex attention 2.00  2.93 79 17.77 <0.001k 2.00
Cognitive flexibility 1.85  2.14 81 16.62 <0.001k 1.85
T0-T3 Pairs{ Mean Difference  SD Number of Patientsy t Test p Value Cohen’s dz
Verbal memory 0.01  1.14 71 0.09 0.93 0.01
Visual memory 0.09  1.31 75 0.60 0.55 0.07
Processing speed 0.15  1.12 79 1.19 0.24 0.13
Psychomotor speed 0.33  1.57 79 1.88 0.06 0.21
Reaction time 0.18  2.32 76 0.67 0.51 0.08
Complex attention 0.76  3.01 73 2.17 0.03k 0.25
Cognitive flexibility 0.36  2.15 74 1.44 0.15 0.17
T0, preoperatively; T3, postoperatively.
*Reaction time is based on time components of neuropsychological tests; all other domains reflect response (i.e., correct/incorrect) components of neuropsychological tests.
yThe number of patients differs over cognitive domains as a consequence of missing or invalid scores on the pre- or postoperative assessment.
zCohen’s d effect size: 0.50 ¼ small, 0.51 - 0.80 ¼ medium, 0.80 ¼ large.
xNegative z scores imply lower performance of patients compared with the normative group, and vice versa for positive z scores.23
kp < 0.05.
{Positive change scores imply higher performance of patients on T3 compared with T0, and vice versa for a negative change score.
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normative sample whose performance changed over a 3-month
interval (i.e., to test whether changes were significantly more
frequent in patients with GBM than in controls).
All statistical analyses were performed using SPSS version 24.0
(IBM, Armonk, New York, USA). Alpha was set at 0.05.
RESULTS
Patients’ Characteristics
Figure 1 shows the flowchart of patients with GBM in this study.
At baseline, 125 patients were included. Forty-three patients (34%)WORLD NEUROSURGERY 117: e172-e179, SEPTEMBER 2018did not complete follow-up, resulting in 82 patients with pre- and
postoperative measurements. Table 1 presents sociodemographic
and clinical characteristics of the GBM sample. There were no
significant differences regarding sociodemographic and clinical
variables, and baseline cognitive performance between patients
who completed pre- and postoperative assessment and patients
who dropped out of the study (p values > 0.05; data not shown).
Group-Level Performance
We found significantly lower performance of patients with GBM
compared with the normative sample on all cognitive domains
both before (ES ranging from 0.91 to 2.98) and 3 months afterwww.WORLDNEUROSURGERY.org e175
Figure 2. Percentages of patients with glioblastoma
with a z score in the very low, low, average, or high
category for each cognitive domain, pre- and
postoperatively. Preoperative data are available for a
range of 116e125 patients; postoperative data are
available for a range of 78e82 patients. CNS VS, CNS
Vital Signs; T0, preoperatively; T3, postoperatively.
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(Table 2).
Preoperatively, mean z scores as low as 2.98 and 2.36 were
found for complex attention and cognitive flexibility, respectively.
Postoperatively, the lowest mean z scores were observed for re-
action time (2.22) and complex attention (2.00).
Group-Level Changes
On the group level, paired-samples t tests revealed no significant
changes in neuropsychological performance over time for CNS VS
cognitive domains, except for complex attention, where post-
operative performance was significantly higher (t(73) ¼ 2.17, p ¼
0.03) (Table 2). ESs were small for each cognitive domain, with
Cohen’s d ranging from 0.08 to 0.25.
Individual Performance
Figure 2 shows the percentage of patients scoring within each
category (i.e., very low, low, average, high) for each cognitive
domain. Prior to surgery, 101 patients (82%) showed an
impaired score (z  1.5) on at least 1 cognitive domain,
whereas 67 patients (60%) showed an impaired score on at least
3 cognitive domains. On average, performance of patients was
impaired in 3.2 domains. Cognitive flexibility (n ¼ 72, 62%) and
complex attention (n ¼ 68, 58%) were most frequently affected.
Postoperatively, 68 patients (84%) showed an impaired score on
at least 1 cognitive domain, and 31 patients (41%) showed ane176 www.SCIENCEDIRECT.com WORLD NEimpaired score on at least 3 cognitive domains. Performance was
impaired on an average of 2.8 cognitive domains. Most frequently
impaired were the domains of reaction time (n ¼ 44, 54%) and
complex attention (n ¼ 38, 48%).Individual Changes
Up to 89% (n ¼ 67) of the patients demonstrated reliable changes
in performance in at least 1 cognitive domain from pre- to post-
surgery, whereas 41% (n ¼ 31) of the patients showed reliable
changes in 3 or more domains. The Chi-square test of indepen-
dence demonstrated that changes in at least 1 cognitive domain
were significantly more frequent in patients with GBM (89%) than
in normative controls (49%; c2 (1) ¼ 33.75, p  0.001). The same
held for changes in at least 3 cognitive domains: this was found
significantly more often in patients with GBM (41%) than in
normative control subjects (5%; c2(1) ¼ 41.06, p  0.001).
Half of the 67 patients demonstrating changes solely showed
improvements (51%, n ¼ 34) and 27% of the patients solely
declined, whereas 22% showed both improvements and declines
on separate cognitive domains. Change was most common for
reaction time (55%) and cognitive flexibility (50%); the fewest
changes occurred in verbal (13%) and visual memory (16%).
Forty-eight of the 67 patients (72%) who demonstrated preop-
erative cognitive impairments showed postoperative improve-
ment, and up to 60% of these improvers now demonstrated
unimpaired levels of performance on at least 1 of the preoperativeUROSURGERY, https://doi.org/10.1016/j.wneu.2018.05.232
Figure 3. Number of patients within change categories
(improved, stable, or declined) displayed against
preoperative performance categories (very low, low,
average, or high) of patients with glioblastoma. For
example, 5 patients scored low on verbal memory
preoperatively, of whom 2 patients improved, 2
patients were stable (i.e., score remained low), and 1
patient declined after surgery.
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was most common for reaction time (n ¼ 25, 31%) and psycho-
motor speed (n ¼ 23, 28%). Performance of 14 patients (21%)
declined even further after surgery on domains that were already
impaired preoperatively. Further decline was most common for
reaction time (n ¼ 8, 10%) and cognitive flexibility (n ¼ 7, 9%). Of
the 75 patients who showed unimpaired performance on domains
preoperatively, 33% (n ¼ 27) showed postoperative decline in
these domain(s); in 70% of those with declines, performance
dropped to an impaired level. Declined performance in previously
unimpaired domains was most common for reaction time (n ¼ 15,
18%) and psychomotor speed (n ¼ 9, 11%). Fifteen percent (n ¼
12) of the patients showed further postoperative improvements on
preoperatively already unimpaired domains, which was most
common for reaction time (n ¼ 4, 5%) (Figure 3).DISCUSSION
This study evaluated cognitive functioning before and 3 months
after surgical treatment in patients with GBM using a computer-
ized clinical neuropsychological battery to compare group and
individual changes.WORLD NEUROSURGERY 117: e172-e179, SEPTEMBER 2018We found extensive (i.e., mean z scores ranging from 0.69
to 2.98) pre- and postoperative cognitive deficits in cognitive do-
mains for patients with GBM on the group level. Correspondingly,
the vast majority of patients (>80%) showed impaired performance
on at least 1 cognitive domain pre- and postoperatively when looking
at individual patients with GBM. This corresponds to prior
studies using conventional paper-and-pencil neuropsychological
tests.6,9,20,24 Complex attention, cognitive flexibility, and reaction
time were most severely impaired (z scores ranging from 1.85
to 2.98), but also most frequently impaired following from the
individual patient analyses. As many social, family, and professional
activities rely on abilities covered by these cognitive functions (e.g.,
switching between tasks or conversations, decision-making, con-
trolling behavior), patients are likely to experience far-reaching
consequences of these impairments in their daily lives.34
Compared with other studies, we found relatively few impairments
in verbal and visual memory.6,9,20,21 CNS VS memory tests do not
include a free recall condition, but solely rely on recognizing items,
whereas studies reporting higher rates of memory impairments
assessedmemory performance using free recall conditions.6,9,20,21,24
This might explain the lower rate of memory impairments in the
current study.www.WORLDNEUROSURGERY.org e177
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the group level were found from pre- to postsurgery. However,
when using RCI values representing reliable changes in perfor-
mance in individual patients, up to 89% of the patients showed
substantial changes on at least 1 out of 7 cognitive domains over
time. Half of these patients solely showed improvements, a
quarter solely showed declines, and another quarter of the patients
showed both improvements and declines. These findings clearly
demonstrate that group results mask changes on the individual
level.
Although postoperative improvement in performance was
common, this does not imply return to unimpaired levels of
cognitive functioning: more than one third of the patients who
showed postoperative improvement on preoperatively impaired
domains remained impaired (since performance can improve from
very low to low). Individual change (both improvements and de-
clines in performance) was most common for reaction time.
Overall, it seems that the lower the performance the more
improvement, and the higher the performance the more decline
for the different cognitive domains (Figure 3). From a
methodological point of view, very low performance leaves the
most room for improvements, whereas higher performance
leaves the most room for decline. At the group level, only
performance on complex attention improved significantly after
surgery.
The rates of individual changes in cognitive performance in
patients with GBM described in this study were higher than
change rates that were found in prior studies (e.g., ranging from
24% to 49%6,20). This may be because of different definitions of
change that were used over studies. For example, according to
Habets et al.,6 clinically significant improvement was defined as
an increase in z score of at least 1.5 SD from baseline to
follow-up, and also, if the follow-up score fell into the normal
performance range of controls. Talacchi et al.20 used yet another
definition of change, as impairments had to be less frequent
(i.e., fewer domains impaired) or more frequent (additional
domains impaired) to speak of changed performance.
Furthermore, follow-up assessments in these studies were con-
ducted at an earlier stage (i.e., acute postoperative phase,20 3
weeks after surgery6), whereas patients in the current study were
assessed substantially later after surgery, when chemo- and/or
radiotherapy had already started in most patients.
Of the preoperatively assessed patients, 66% also completed
postoperative neuropsychological evaluation. Considering the
severity of the illness and its profound treatment, this number ise178 www.SCIENCEDIRECT.com WORLD NErather high, also when compared with other follow-up studies in
patients with GBM.6,35,36 The good retention of patients may be
explained by the fact that the neuropsychological assessment was
an essential part of clinical aftercare that was combined with other
clinical appointments, and by the use of a rather short cognitive
instrument. Implementing a brief neuropsychological assessment
in the clinical care of patients with brain tumors is an important
step towards actually using neuropsychological information in the
clinical management of these patients. Since patient burden (in
terms of energy and time) should be limited, the CNS VS may be a
suitable and valuable method. However, one might consider
supplementing the CNS VS limited memory tests (i.e., solely
relying on recognition) with memory tests that also appeal to
retrieval and learning efficiency.
We solely included patients who were considered appropriate
candidates for surgery and capable of pre- and postoperative
neuropsychological assessment. Consequently, results are likely
biased toward an overestimation of cognitive performance in pa-
tients with GBM in general.
As a consequence of multimodal treatment of GBM, survival in
patients with GBM has improved with overall survival reaching
27% at 2 years.31,37 Future studies should examine predictors of
(changes in) individual cognitive performance, its effects on daily
functioning and quality of life, and examine the longer-term
course of cognitive functioning in patients with GBM.CONCLUSIONS
We found extensive and serious cognitive impairments both
before and 3 months after surgery in patients with GBM assessed
using a computerized neuropsychological battery. At the group
level, only minimal changes in neuropsychological performance
occurred from pre- to postsurgery, whereas substantial differences
in change were found at the individual level, with 89% of the
patients changing on at least 1 cognitive domain. Half of these
patients showed solely improvements, a quarter showed solely
declines, and another quarter of the patients showed both im-
provements and declines. These findings clearly demonstrate that
group results mask changes on the individual level. Future studies
should therefore (also) employ an individual patient approach to
enhance knowledge transfer into clinical practice. Furthermore,
methodological confounds, such as practice effects, should be
controlled for in research and clinical settings when statements
about (changes in) cognitive performance of the individual patient
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